you very call been two today, welcome quarter especially status our to like December year CG'XXX year malignancies. we to Aptose the of the I'd for and a for for XX, update hematologic APTO-XXX, much and XXXX. have being Michael. everyone and to products on ended developed you, our It's productive Thank
discuss and other initiatives, upcoming we timelines. milestones addition will In
Greg we'll Chow quarterly for Mr. financials CFO our updates, will and our then call the question. open these Following review your
dogs. the up characterized cause These some and appears might typically which the is we toxicities. rodent in sensitive news. did generally welcome toxicities rest by range Yet, cause successfully maximum are to unexpected at rodents and studies studies reach that which report was I’m complete levels toxicity have with put this exposure per we as XXX pan-FLTX/pan-BTK per dose. feasible developed highly we B-cell to that some from it, CG’XXX the AML to during XXXX or begin course class and as clinic. call we inhibitor in oral being CG’XXX close of And getting how are first-in made wants an into Let's everyone addressing malignancies. we a with know a for To in patients certain route progress of begin, with multi-kinase our synthetic human first and prior well of API batch that deal calls, reported we needed substance the in that of scale highly finding to XXX API accepted pleased dose we CMC in for completed XXXX milligrams the the trials. of purified studies. manufacturer manufactured and matters In or PK had formulation to solved range quarterly and dose the we sufficient safety finding dosed kilogram the for drug that great And very dose. high that not still This data even dogs XXX day to
will assume hope robust the bone that animals to because to humans. perform to that will and hit into do appear are toxicities dosing, targets longer-term we continues a toxicities in therapeutic we we suppression those by trend expect to the bone we marrow Yet marrow still XXX. window related observe suppression. we as began assume We be to be related However, likely and have
mentioned the call, have understanding of we clinic kilogram the manufacturer this confidence batch dogs. malignancies. for to initiated into of Further upcoming cover during submit already on trials that Those be for are X.X in progress year prepared we an trials in as our both and to the second submit and IND AML IND studies to good And I will advanced the rodents GLP the make that trials. such safety an enabling to track on studies immediately last continue and remain for of scheduled we and enabling latter pharmacokinetic GMP quarter and clinical we XXX portion have Plus have to used both We batch of the IND a year. have during begin manufacturing now move in B-cell scientific now added IND this thereafter.
and recently for regulatory but As because a matters. designation kinase inhibitor mutations provided ITD moving in to in region. of Food so of asset. support these and the of approved we granted development as referred embattled Drug in orphan Having midostaurin AML for now FLTX timelines key drug other the the mutation drug compelling XXXX, and few kinase. AML. reminder, tyrosine the marrow resistance FDA's the cancer is the the patients U.S. accelerator blood you about AML orphan with to assigns medicines the beyond during devastating patient with to ITD we’re inhibitors patient receptor office us designation have FLTX the for spend FDA XXX ITD driver a and occur are and the why this or patients. of of and underserved in kinase of a in one-third is drug tyrosine the to FLTX bone benefit have given drug that And announced disease The Administration for CG’XXX revisit products domain approximately this FLTX fourth population gatekeeper mutation excited remain orphan quarter that clinic these let reviews agents me the anticipated a provides The into minutes development
prominence been the with mutant the to all harboring shown forms retains very resistant it FLTX nanomolar to gamut disease Yet Why most inhibit it which AML forms effect Because against XXX that poor from compound profound drive cells. that true pan-FLTX the are inhibited is marrow human and mere lower malignant derived essential kinases rescue HXSXX including still this if AKT, ERK, XXX important? upon even the mutations. a control only that lines including BTK, relevant and more Our of for and antileukemic exert insufficient impress AML picomolar of CSFXR, inhibitors. kinases, meaning mirroring to studies, FLTX exert that XXX us potency that is other is potent cell prognosis FLTX to of related known and clinically FLTX in has In rendered pathways bone is AML. leukemia malignancies inhibitor. associated Aurora the to compartment. of the Other is for than The against are you FLTX clusters all inhibitor preclinical forms others
wall set thus sufficiently Similarly, cells animals. FLTX other additional pathways rescue pathways and and a B-cell it XXX type diverse the cancer well-tolerated malignancy cells range BTK of B-cell yet kill forms and the remain across and suppresses of exert a cells. XXX and these broad to mutant of suppresses rescue ability in operative by However, killing that of diversity can AML the
caused Andreeff MD Some in Health Knight Dr. in at XXXX our under bone of simultaneously by other Dr. Cancer and Anderson’s of three MD poster Michael the of the exciting ASH by agents. to multiple XXX University, cells Brian were resistance & December range and kill researchers subject ability Anderson to partners presentations presented marrow act AML Druker. Center Data overcome with of pathways prestigious unique with those Science elucidated the under broad presented Center Cancer suppressing a cells to preclinical stromal the Oregon conjunction by synergistically of data research
cells inhibitors at in of the the data the pathway, as XXX BTK, been to ability plus eliminated a multiple presented FLTX AML circulating form killing antileukemic ability of ligand and of additional in XXX FLTX. Aurora cells. set broad just ERK derived striking Druker over depending the Anderson OHSU XXX Notably, presentation and MD a more XXX marrow as well study mechanism to the poster the in to of stromal of ITD, cell midostaurin, XXX. a also by demonstrated expressed have inhibitors by are AML program through patient’s AML the cells or development. FLTX hypothesis was differentially competitor is mechanisms and AKT, FLTX well with underscore vivo against those bone the in in these signaling host of of suppress FLTX patient cells for cells operative AML. Specifically, corporate to background differentiation in supported gatekeeper presence that tyrosine pathways FLTX elucidates XXX death cells kinase, heat and other subgroups from FLTX CSFXR, data the of our antitumor FLTX development and and patients Cancer a data XXX as ASH other involvement from mutations, with demonstrated to cells all wall AML activity XXX of different XXX those agents. type kill A evaluated from of broad-spectrum Separately on in model genetic is patients demonstrated and sensitivity AML illustrate and under that of overcome inhibitor. ITD In data Remarkably, the that FLTX other superior kinase and its maintain sensitized seen further Center map FLTX cells domain hundreds that AML marrow of inhibitors. XXX presented quizartinib Brian separate with potency dose-dependent ability AML or the resistance Knight a samples bone diverse and malignant in as presentations the to Together XXX of These than in inhibitors AML pathway the Dr. standard chemotherapy
how grows, normal AML to of mechanistic and molecule framework kinases are understanding heterogeneous of XXX can group our without observed specific cells. construct in of toxicity As single clusters of cells we a beginning inhibit
XX% of In to Ohio addition ibrutinib approximately reiterate here the I that to refractory XXXX the studies multi intolerant various diverse an by standard Based XXX sales all potency in billion to performed X.X target to has with care. discontinued is fold lines proving and XX% being cells, at of dollars be inhibitor University, a Yet than which approximately BTK of or to State kills to malignancy vitro approximately cell a team treatment greater ability to on current with the set AML resistant approximately XX% noncovalent ibrutinib worldwide and years FLTX estimated act annually. with ibrutinib a B-cell after the treatment. patients of on X% also XXX want half of
ibrutinib medical opportunity. among continued market significant unmet So with the need comes patients the discontinuing
the with broad against potency cell greater refractory to patients refractory potently maybe its researchers covalent of treatment disease. bone lymphocytic malignancies and on Cancer XXX as full myelodysplastic ASH XXX subtypes ibrutinib. samples tolerate due Cysteine BTK allowing over that and Beat of to marrow patients directly in or than of ibrutinib treatment malignancy malignancies. rescue the patients including various the patients allow CML, to presented a findings an Through inhibitors resistant activity And set to other inhibitors. leukemia. to specimens these this to XXX is treat and ibrutinib XXX from and form or diverse the treating useful covalent cells, XXX important to CERI and the of properties addition multiple ibrutinib. Initiative from OHSU mutant potent they BTK inhibitors. XXX. discontinue noncovalent which many residue Knight around that is against primary cannot cancer Center BTK other is Plus other go B-cell prove used pathways well In AML, hematologic in finally of primary XXX the range compelling AML, ibrutinib on neoplasms the inhibits XXX potency XXX be a mutated malignancy lines exhibited to syndrome, In inhibitor tolerated myeloproliferative to activity patients and BTK hematologic kinases a are Thereby that resistance acute AML may and in resistant study diverse to Together Also from useful and that at B-cell and option tolerance killing and back patient hematologic CLL evaluated provide retains
of to summary, the corresponding that findings to There on the is presenting it other Meeting reveal us XXX new please website. detail sharing press superior in clinical compelling the and presentations and are in look our AACR data further collaborators with inhibitors. For In studies. at than growing you. and releases continued preclinical or our surrounding and upcoming BTK research forward our all ASH see We that on more XXX has results will development to excitement be to we FLTX April are Annual the see eager of
to molecule clinical turn small the dosing. and first Aptose And XXX to oncogene is timelines So c-Myc path we now discuss which let's on return let’s APTO-XXX. inhibitor of plan expression. to
as During manufactured studies a of reason cause XXXX we XXXX demonstrated at the sterility to step to we of Since sufficient well product marked FDA successfully a determine the bridging return particular supply order one we completed root of to to our release clinical our and failed manufacture last call animal to for stable currently the XXX. that performing completed stability and new We drug supply stability, to of have seek see for the findings process I’m manufacturing of submit formal the drug hold. happy studies, clinic. our us end in now infusion correction drug GMP test to the products the in of as GMP product studies manufacturer of and allowed soluble are the the
so we expect Our dosing respond submit we to in has and related be FDA to XXX response CMC clinical quickly is will the the orphan our we the AML, that quarter the product expect ongoing of were and FDA studies lifted designation soon. because with happen the second providing resume patients next the hold successful step drug which may we will hope to
clinical and an and expansion soon patients we initiate expect couple with in of there as to the dose Xb a those sites hold these open hit participate screening running. for phases A of secured ground our or XXX with we will trial RFB patients and dozen MDS immediately we early reminder a trial. approvals have get escalation as or the sites have AML of both more As do Phase
and trials So we're physicians AML clinical treatment soon, to hopeful eager of the test of the restarting c-Myc patients. for the the XXX are inhibitor
not will studies and and the take not have risk unforced I However, an of rush these error.
the it will the regulates keep or in to efforts our dosing as hope to The several I AML cell the background have soon We and deliberate clinic. proliferation and a just be Myc Because as posted. will eager possible in inhibitor and Myc to normal We growth XXX non-myelosuppressive are Myc patient in have of investigators and here clinic return we we a careful return for to to and times, c-Myc you bit mentioned required. is proto-oncogene apotheosis cells. clinical
has in becomes cancers However and to Myc hematologic often over leaving Myc expressed to it actions bone marrow derived AML inhibit oncogenic cells notoriously protein. the difficult been the including of
an inhibits have as However indications. gene. XXX Because our that key hematologic tumor target solid Myc may of molecule new XXX research for malignancies across suggests approach entirely inhibitor anticancer a it many the in is small expression a application certain represents broader and Myc malignancies, Myc
a one talk molecules. our global APL-XXX of all a about India pipeline to deal will and the agreement even to commercialization we and door certain Aptose's deal will the Earlier This other million we've develop a BET upfront to in of up develop tolerated particular we XXX, is inhibitor oncology, action but milestone at dual part but provides entered expression AACR drugs. accepted to mechanism and development, had for that publication of cells with as for of for announced Some related presentation at learned XXX The $XXX two payments been therapy to and and report well in interactions review receive has for that defined. in that which program rights The with and the has at provides that of path have significant a Avanti the BRCAX action have represented the not function. molecules was is FDA reacquisition Aptose research approved will of particular almost if deficient it as like of the to and kinase OHM XXX, I also potential APL-XXX. molecularly of the goal particular peer hypersensitivity, tumor these learned we Myc synthetic to indication to publications rather and/or results Indeed for the directly protein details XXX. that the It gene lethal is the in exhibit that the The or while exhibits be acts expression. payment molecules. as target and homologous retain functions Sciences Aptose's approved. kinase is the identification to is Life identified The with Aptose Simultaneously, lethality shown new promoter all revealed into how maximum provided third repair for on indication of program. BET the ability in targeted by of stuff eligible does solid related to focus the These exploit upcoming for indications a interesting The unlike protein of XXX XXX region will rights deficiency that of drugs Laxai sublicense does with BRCAX because program. our and inhibit not interest in this Myc and publications. inhibitor XXX rights the month subsidiary manufacture other the gene. the and recombination olaparib molecule dose. of global XXX molecules first was OHM in research further sensitivity myelosuppression other produce XXX. clarify cells ASH two nominal opens inhibitor published license olaparib AML to bromodomain from accepted to of abstracts DNA molecule. now interact royalties APTO-XXX been bromodomain loss inhibits comparable In We synthetic of we’re but
evolve lead action As drugs several develop with to for you protein program. to Inhibitors inhibitor oncogene. epigenetic regulate recall, the from an LALS their expression BET represent molecules work earlier because of ability pharmaceutical BET companies class APL-XXX the pursued being of by interesting Myc of may kinase dual bromodomain of
an to unacceptably led molecule. APL-XXX priority bromodomain tend a to effort be BET sort activity to simple engineer additional inhibitors to and so as However, That molecule. we inhibitory toxic the kinase
it it by future. in additional a has driven for means finds encouraged and to patients and transaction cancer as meaningful for to this home are in potential oncogenic non-core Moreover Aptose funding an non-diluted the We a cells. bring target to new processes agents provides Myc asset the
come during and year more one We far in towards look have important milestones XXXX.
the More our advanced importantly and such year ongoing an XXX to this support to B-cell looking over the of IND the back our we’ve I in turn and you Xb trial that Chow programs. pipeline we we Chief now submit plan plan quarter. to Phase AML AML NDS will Officer, return reporting to will results to who to forward of and malignancies. for XXX in those we're review call And to trials on patients both Financial Greg
